Source comparison
The Quantified Risk: Sermorelin vs Steroid Safety Data
Numbers tell the story more clearly than qualitative comparisons. The following data quantifies the actual risk differential between these two classes of compounds. Sermorelin was used in FDA-supervised clinical trials involving over 800 pediatric patients wit
This comparison does not assign a generated winner or score.
- Numbers tell the story more clearly than qualitative comparisons. The following data quantifies the actual risk differential between these two classes of compounds.
- Sermorelin was used in FDA-supervised clinical trials involving over 800 pediatric patients with no serious adverse events attributed to the peptide (Walker, Endocr Pract, 2006). The most common complaint was injection site irritation. No cardiovascular events, liver damage, endocrine disruption, or deaths were reported.
- Anabolic steroid adverse events are extensively documented. A systematic review by Pope et al. (2014) found that AAS users had a 4.6-fold increased risk of cardiovascular events compared to non-users (Pope et al., Endocr Rev, 2014). Baggish et al. (2017) showed that AAS users had mean left ventricular ejection fractions of 52% versus 63% in non-users, a clinically significant difference indicating cardiac dysfunction (Baggish et al., Circ Heart Fail, 2017).
- Liver toxicity from oral steroids produces measurable enzyme elevations. A study of bodybuilders using oral AAS found ALT elevations exceeding 3x the upper limit of normal in 56% of participants. Peliosis hepatis, a potentially fatal condition of blood-filled liver cysts, has been reported in numerous case studies of chronic oral AAS users.
- Cardiovascular event risk increase
- Not documented
- 4.6x baseline (Pope et al., 2014)
- Liver enzyme elevation (>3x ULN)
- 0% in clinical trials
- 56% of oral AAS users
- HPTA suppression
- 0%
- 100% (dose-dependent severity)
- Deaths attributed to the compound
- 0 in published literature
- Multiple case reports
- Psychiatric adverse events
- 20-30% of users report mood disturbance
- For related peptide safety information, see our peptide safety guide. For understanding how other peptides compare in terms of safety, see our articles on tesamorelin dosage for fat loss and MOTS-c peptide dosage.